HC Wainwright Reaffirms “Buy” Rating for Nyxoah (NASDAQ:NYXH)

Nyxoah (NASDAQ:NYXH)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a research note issued on Friday, MarketBeat reports. They presently have a $17.00 price target on the stock. HC Wainwright’s price target would indicate a potential upside of 112.50% from the stock’s current price.

Separately, Cantor Fitzgerald reiterated an “overweight” rating and set a $16.00 price objective on shares of Nyxoah in a research note on Tuesday, November 5th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Nyxoah has a consensus rating of “Buy” and a consensus target price of $17.00.

Nyxoah Price Performance

Shares of NASDAQ:NYXH opened at $8.00 on Friday. The firm has a market capitalization of $199.52 million, a PE ratio of -4.28 and a beta of 1.35. The company has a quick ratio of 4.95, a current ratio of 5.28 and a debt-to-equity ratio of 0.21. The company has a 50-day moving average price of $8.86 and a two-hundred day moving average price of $8.53. Nyxoah has a twelve month low of $4.00 and a twelve month high of $20.00.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Nyxoah stock. Kovack Advisors Inc. purchased a new position in Nyxoah S.A. (NASDAQ:NYXH) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 10,000 shares of the company’s stock, valued at approximately $96,000.

Nyxoah Company Profile

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.